A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
- Mechanism
- Curator reviewed
Probucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. This drug may also act to inhibit the initial stages of cholesterol synthesis and act to inhibit the absorption of cholesterol from the diet. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis. It appears to inhibits ABCA1-mediated cellular lipid efflux.
- Primary indication
- Used to lower LDL and HDL cholesterol.Curator reviewed
- Formula / weight
- C31H48O2S2 · 516.842 g/mol (avg)
- First approval
- Canada, 2006
- Also known as
- Biphenabid · Bisbid · Bisphenabid
- Code names
- DH-581
Resolves to
FYPMFJGVHOHGLL-UHFFFAOYSA-NSMILESCC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Probucol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account